NRXP (STOCKS)
NRX Pharmaceuticals, Inc. Common Stock
$4.068700
+0.228700 (+5.96%)
Prev close: $3.840000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jonathan C. Javitt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $171.34M
- Employees
- —
- P/E (TTM)
- -3.19
- P/B (TTM)
- -9.88
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $2.29M |
| Cost Of Revenue | $1.14M |
| Costs And Expenses | $19.41M |
| Nonoperating Income/Loss | -$7.42M |
| Operating Expenses | $18.28M |
| Selling, General, and Administrative Expenses | $13.93M |
| Depreciation and Amortization | $133.00K |
| Research and Development | $4.28M |
| Operating Income/Loss | -$17.12M |
| Income/Loss From Continuing Operations After Tax | -$24.54M |
| Income/Loss From Continuing Operations Before Tax | -$30.97M |
| Income/Loss From Equity Method Investments | $37.00K |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$24.54M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$24.54M |
| Net Income/Loss Available To Common Stockholders, Basic | -$24.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.09 |
| Basic Average Shares | 75,010,412 |
| Assets | $11.90M |
| Current Assets | $7.36M |
| Noncurrent Assets | $4.54M |
| Fixed Assets | $259.00K |
| Intangible Assets | $879.00K |
| Other Non-current Assets | $3.40M |
| Liabilities | $25.72M |
| Current Liabilities | $25.18M |
| Accounts Payable | $4.40M |
| Wages | $394.00K |
| Other Current Liabilities | $20.38M |
| Noncurrent Liabilities | $543.00K |
| Equity | -$13.82M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$13.82M |
| Liabilities And Equity | $11.90M |
| Net Cash Flow From Operating Activities | -$14.93M |
| Net Cash Flow From Operating Activities, Continuing | -$14.93M |
| Net Cash Flow From Investing Activities | $1.08M |
| Net Cash Flow From Investing Activities, Continuing | $1.08M |
| Net Cash Flow From Financing Activities | $19.12M |
| Net Cash Flow From Financing Activities, Continuing | $19.12M |
| Net Cash Flow | $5.27M |
| Net Cash Flow, Continuing | $5.27M |
| Comprehensive Income/Loss | -$24.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$24.54M |
| Other Comprehensive Income/Loss | $23.09M |